29th Annual Pharmaceutical / Chemical Patent Practice Update
Hotel Woodbridge at Metropark
120 Wood Avenue South, Iselin, NJ
(732) 494-6200
Program: Thursday, October 22nd 12:00 - 5:30 p.m.
Event Fee: $125 Corporate / Government Employee
$100 Corporate / Government Employee - NJIPLA Member
$225 General Registration
$180 General Registration - NJIPLA Member
Agenda:
12:00 - 1:00 p.m. Luncheon
1:00 - 1:05 p.m. President’s Introduction
Jon A. Chiodo, Johnson & Johnson
1:05 - 1:10 p.m. Opening Remarks by the Chair
J. Eric Thies, Merck
1:10 - 2:45 p.m. Biotechnology and Pharmaceutical Issues in the
European Patent Office (EPO)
Inventive Step in Biotechnology, Examination
Practice at the EPO
Laurent Deleu, PhD, Examiner, EPO
Medical Use Claims Under the European
Patent Convention
Virginie Merckling-Ruiz, PhD, Examiner, EPO
Patentability of “Antibodies” Under the
European Patent Convention
Wolfram Meyer, PhD, Examiner, EPO
2:45 - 2:55 p.m. BREAK
2:55 - 3:30 p.m. The Road Less Traveled: The 505(b)(2) Pathway
to FDA Approval
Rabiya Kader, Sanofi
3:30 - 4:05 p.m. PTAB Update: Where We Are After Three Years
of Challenges to Orange Book Patents
Gregory A. Morris, Honigman Miller Schwartz
and Cohn LLP
4:05 - 4:15 p.m. BREAK
4:15 - 4:50 p.m. § 101: Is it really the “End of the World as We
Know It”? A breakdown of where we are now
and what to expect
Grantland G. Drutchas, McDonnell Boehnen
Hulbert & Berghoff LLP
4:50 - 5:30 p.m. Patent Litigation Under the BPCIA: Impact of
Recent Decisions on Strategies for Addressing
Potential Patent Disputes
Elizabeth Weiswasser, Weil, Gotshal &
Manges LLP
CLE: 4.5 NJ & NY
4.0 PA